Researchers have fully enrolled a clinical trial to test a new drug called bezisterim for treating neurological symptoms associated with Long COVID. This trial, named ADDRESS-LC, aims to evaluate how well bezisterim can alleviate issues like brain fog, fatigue, and cognitive dysfunction that affect many of the estimated 15 million U.S. adults suffering from Long COVID. Currently, there are no FDA-approved treatments for these debilitating symptoms, making this trial particularly significant for those seeking relief.

For people experiencing Long COVID, the potential benefits of bezisterim could be substantial. The drug is designed to target inflammation in the brain, which is believed to play a key role in the persistence of neurological symptoms. The trial involves around 200 adult participants who will receive either bezisterim or a placebo, with the primary goal of measuring improvements in cognitive function and fatigue. If successful, this could offer a new avenue for those struggling with the cognitive and emotional toll of Long COVID.

The ADDRESS-LC trial is a Phase 2 study, which means it is still in the early stages of testing. While the results are eagerly awaited, with topline data expected in late summer 2026, it’s important to note that the findings are not yet conclusive. This trial is part of a broader effort to understand and address the long-term impacts of COVID-19, particularly in the realm of neurological health.

For those interested in managing their health, staying informed about the progress of this trial could be beneficial, especially if you or someone you know is dealing with Long COVID symptoms. Engaging with community resources and support groups may also provide additional strategies for coping with these challenges as research continues.

Source: globenewswire.com